Issue 2 / From Idea to Impact

The long road from
world-class research to
better health outcomes


Great ideas often emerge from unlikely origins: an accidental discovery, re-thinking a failure, or when challenged by a new point of view or question. But an idea alone is not enough to change the world.

For research to leave the lab, or the academy, and find footing in the greater world, it takes new skills, work both exciting and mundane, collaboration with unlikely partners, an enormous amount of time, and creative thinking to surmount obstacles and stay the course from idea to global impact.

In this issue of Spark, we look at the experiences of four MSFHR-supported researchers whose journeys led them across the unique terrain of developing new technologies and businesses, and instigating policy and practice change.

Their stories illustrate BC’s tremendous potential for world-class research, and the unique environment and infrastructure that transforms ideas into improved health.

Chapter 1:

Proof of Concept

In many parts of the world, a lack of access to basic monitoring equipment makes anaesthesia unsafe. With death rates due to anaesthesia and surgical complications two to four times higher in developing countries than in the developed world, MSFHR Scholar Mark Ansermino and his colleague Guy Dumont asked a simple, powerful question: "How can we make anaesthesia safe for everyone?"


Their answer has spawned an innovative medical device, a BC-based biotech company, international clinical trials, and the potential to someday soon save thousands of lives around the world.

But their journey has by no means been a straight line.

Determined to make anaesthesia safe for everyone, the pair devised and built a prototype oximeter to measure a patient’s blood oxygen saturation using an ordinary mobile phone – an innovation with great promise to make a life-saving technology affordable and accessible in all settings.

With a home-built prototype in hand, the researchers carried out early tests in Uganda that showed the device’s potential.

While Ansermino saw the phone oximeter's capability in the field for anaesthesia, he realized the device had many other potential applications. A chance conversation over coffee with his colleague Peter von Dadelszen led to an “accident of research."

Describing his work on a risk-assessment model for pre-eclampsia, a serious elevation of blood pressure during pregnancy, von Dadelszen noted that the women who experienced the greatest complications suffered from low oxygen saturations — precisely the outcome the phone oximeter was created to measure.

1 billion

people worldwide do not have access to safe, affordable surgical care.

Recognizing the synergy in their projects, the two researchers integrated phone oximetry into a predictive model of pre-eclampsia risk. The partnership has grown into a large international trial in four countries — India, Pakistan, Nigeria, and Mozambique — with more than 80,000 women enrolled.

Expanding the phone oximeter's scope stands to benefit many more patients, but also increases the costs of bringing the device to market.

"We can solder this together in our basement and prove a concept, but there’s a huge step in actually making that into a commercial product," Ansermino says. "What we really needed was to establish a company to manufacture these devices."

Enter Tom Walker, an experienced BC-based biotech entrepreneur, who saw the news coverage of the device and was excited by the possibilities. Working with Ansermino’s team, Walker spearheaded development of a start-up company, LGT Medical, focused on producing the device.

But he didn't come with money, we still had to go to Grand Challenges Canada to try and raise some of the funds.

The team also attracted funds from local investors, enabling them to move forward with development of a commercial version of the phone oximeter.

"We're still not there yet," says Ansermino. "It's like with all start-ups, we don't have enough revenue to sustain us, so we're still looking for ways to keep this going for a few years so we can build sales and get to the stage where we are sustainable as a company."

Research Outcomes:

Phone Oximetry

Mark Ansermino’s phone oximeter is poised to transform the way health care workers in resource-limited settings diagnose and treat a range of conditions.
  • For only $50, the device will put the ability to measure blood oxygen levels in the hands of anyone with a smart phone. Equivalent hospital technology costs several thousand dollars.
  • Oxygen saturation data will make anaesthesia and surgery safer, allowing developing countries to meet international standards of monitoring.
  • The phone oximeter will aid early diagnosis of infectious diseases such as pneumonia, which kills more than one million children annually. And it will improve risk-assessment for women with pre-eclampsia, accurately identifying those who require urgent medical intervention 48 hours to seven days in advance.
Chapter 2:

Discovery, to Approval, to Market

The advent of genome-wide technologies in the 2000s heralded a revolution in cancer research. But as genomic data sets grew in size and complexity, BC Cancer Agency/Vancouver General Hospital scientist Torsten Nielsen wondered how we could find clinical meaning among the reams of data.


Backed by an MSFHR Scholar Award and a grant from the US National Institutes of Health, Nielsen and his team spent five years perfecting a test that could filter through thousands of genes expressed by breast cancer. Their work identified a list of 50 genes that could be measured efficiently from biopsy specimens to classify tumours into one of four main sub-types.

"We had for the first time these tools that generated huge amounts of data, but we needed to turn that data into information, and information that we could use to help people," Nielsen says.

The resulting test – called PAM50 – had immense clinical potential. Accurately classifying tumour sub-types would allow physicians to make targeted treatment decisions that could save lives and reduce costs.

But a test that works in the lab is not the same as a test that can be commercially marketed and used to make life-or-death decisions in the hospital.

For their investment of five years of time and resources, Nielsen’s team had achieved proof of concept. The next challenge was to figure out how that concept could be scaled up for maximum impact.

The testing required to validate a discovery for regulatory approval is not only repetitive, but expensive. Researchers must show analytical validity – consistent results across a range of conditions – as well as clinical validity – a test or device’s ability to accurately predict patient outcomes in repeated use.

In 2011 in BC,


women were diagnosed with breast cancer.

Public grant funding won’t typically cover the types of studies required for regulatory approval. So, for many researchers, the only way to navigate this complex process is to enlist a commercial partner.

Nielsen formed a partnership with Seattle-based NanoString Technologies that opened the door to commercializing his PAM50 breast cancer test. It also opened his eyes to the private sector’s approach to milestones, timelines, and strategic decisions.

Devoting precious time to the demands of commercialization can be a career liability for researchers who operate in a world where publication success and funding depend more on novelty and innovation than on following through on technical details.

“It’s an opportunity to do things that are somewhat higher risk for your career but ultimately give us a better chance of really moving research forward into health care and helping the patients of British Columbia and indeed of the world,” he says.

With the support of MSFHR and his commercial partner NanoString, Nielsen has achieved approval for the PAM50 test from Health Canada, the U.S. Food and Drug Administration, the European Union, and a host of other jurisdictions, including Hong Kong and New Zealand.

Research Outcomes:

Breast Cancer Diagnosis

Torsten Nielsen's PAM50 test is in clinical use around the world under the brand name Prosigna.
  • The test helps identify roughly one-third of early breast cancer patients whose tumours are of a low-risk subtype and whose likelihood of survival without chemotherapy is greater than 95%.
  • The PAM50 test gives patients and families the confidence to avoid chemotherapy, and helps ensure medical resources are deployed more efficiently.
  • The test was recognized by The Scientist magazine in 2013 as one of the year’s top ten innovations in the world.
Chapter 3:

Changing Beliefs

Despite a pilot program that showed home births attended by registered midwives were as safe as hospital birth for selected low-risk women, many jurisdictions and professional associations continued to recommend against home birth. MSFHR Scholar Patricia Janssen wanted to change that.


Like many researchers whose work touches on key policy areas, Janssen found the publication of her findings marked the end of one long and rigorous process and the beginning of another.

For more than a decade, she had been building an evidence base to inform the conversation around home birth and midwifery regulation in BC, Canada, and around the world.

Janssen’s evaluation of BC’s home birth demonstration program in the 2000s led to the addition of home birth as an option for low-risk women under the jurisdiction of the College of Midwives of BC. But despite the evidence, many jurisdictions and professional associations continued to recommend against home birth.

Midwife-attended home births have increased


in BC from 2009/10 to 2013/14

Previous studies had been limited by short timeframes and small samples, and Janssen realized that the home birth policy debate sorely needed long-term follow-up data in a large population.

"Policy requires rigorous studies that are reproducible, that involve large groups of representative people, and that’s what we provided," she says.

Using British Columbia's unique and world-leading health data resources, Janssen assembled a complete database of all home birth outcomes over a five-year period. By comparing these to midwife- and physician-attended home births for women of comparable low-risk status, she was able to assess the relative rates of perinatal death and adverse outcomes.

We’re a very data-rich country. In British Columbia, we have Population Data BC, and it was necessary to use that data, combined with data from Perinatal Services BC, to look at our outcomes... access to those data sources was critically important to us.

The study, published in 2009 made an emphatic case for the safety of home birth attended by regulated midwives in BC. Not only was the rate of death low and comparable to hospital birth, the rates of obstetric interventions and adverse outcomes were in fact lower.

Janssen knew her study could inform policy development at the provincial, national, and international levels, but she needed to get the word out. Working with UBC’s media relations team, Janssen issued a press release highlighting the study’s findings. The response was astonishing.

“We had saturation of every major newspaper in North America, every syndicated evening news show, every major radio network,” she says. “It went all over the world very, very quickly."

It also became a hot topic discussed on social media and blogs, igniting a public conversation about home birth. For her efforts, Janssen received the UBC President’s Award for Public Education through Media.

But the real reward was the surge in awareness among policy-makers. Backed by the study’s strong data, in the Prairie provinces, the Atlantic provinces, and the North. Internationally, legislation to ban home birth that had been before the Australian parliament was withdrawn in light of the study’s evidence.

In BC, the College of Physicians and Surgeons made the unparalleled landmark decision to allow its members to conduct birth at home. And the Ministry of Health affirmed its support for home birth and midwifery, with then-health minister Margaret MacDiarmid recommending the option.

Finally, after more than a decade, the evidence was speaking for itself.

Research Outcomes:

Home birth and midwifery regulation

Patricia Janssen's 2009 study changed the conversation on home birth and midwifery.
  • Since publication, the study has supported midwifery regulation in several Canadian provinces and territories, and in British Columbia, the Ministry of Health now provides additional funding to cover a second attendant at home birth.
  • In 2013, the College of Physicians and Surgeons of BC began to permit its members to attend home births. This change was a boon to rural communities, as physicians and midwives could now share on-call duties, increasing care coverage in resource-limited areas.
  • Internationally, the Australian government abandoned proposed legislation to ban home birth after reviewing the study’s evidence. Other countries, such as the Netherlands, have used the study to help inform their own home birth evaluation models.
Chapter 4:

Changing Practice

HPV infections cause nearly all cases of cervical cancer, the second most commonly diagnosed cancer in women worldwide. To overcome vaccination barriers, Gina Ogilvie and Simon Dobson asked what if we could give young girls fewer doses of the human papillomavirus (HPV) vaccine with no ill effect?


Three doses was the approved global standard, but not necessarily the optimal number. “The cost of getting a vaccine from development through to being licenced is huge,” says Dobson. “The companies don’t want to disadvantage themselves by using fewer doses than would show a result.”

If a two-dose regimen could be proven effective, the impact would be massive. Fewer doses would mean greater compliance and lower delivery costs – effectively, more girls could be immunized for the same investment of resources. It’s an exciting prospect in Canada and a potential game-changer in the developing world.

To answer the question, Ogilvie and Dobson needed to conduct a large study involving thousands of girls, assemble a talented interdisciplinary team, and earn the support of clinicians, policy-makers, and public health specialists. Fortunately, they were in the right place.

“I think one of the things that made this study unique and feasible was that we did it in British Columbia,” Ogilvie says, rattling off half a dozen provincial institutes that supported the work*. “We tapped into all of those infrastructures and all of that expertise to build the team, to build the methodology, to do the analysis, to do the roll-out. Having worked in other provinces, I know those don’t exist everywhere.”

One dose of HPV vaccine costs about $100. Reducing the number of doses from 3 to 2 can save the health system


Equally valuable were the national collaborations they fostered with researchers in Quebec and Nova Scotia that allowed them to expand the study’s scope.

“We’ve been asked this question many times: could you have done this study in any other country?” says Dobson. “And the answer is: I’m not sure that we could, because there’s such good collaboration across Canada and across these different clinical specialties.”

Their study, published in April 2013, proved that over a three-year follow-up period,

* Provincial institutes that supported their work:

  • BC Cancer Agency
  • BC Centre for Disease Control
  • BC Children's & BC Women's Hospital
  • Public Health & Microbiology Reference Laboratory
  • Vaccine Evaluation Centre
  • Women's Health Research Institute

Even with this strong evidence for the benefits of two doses, there was no guarantee their recommendation would be adopted as policy.

“There’s in-built conservatism, and quite rightly, about changing an immunization schedule away from what’s been licenced for the product,” says Dobson, “and so it is a leap of faith to use less than the three doses.”

Convincing policy-makers to take that leap of faith was their next task. But for Ogilvie and Dobson, the process of persuading policy-makers had started even before their research question was settled.

With the introduction of the HPV vaccine in 2006, it was widely recognized that the vaccine would have resource and policy implications for governments.

At a summit attended by public health experts, clinicians and Canadian researchers from the vaccine and cancer fields, the question of optimal dosing emerged as a top priority with broad support among scientists and policy-makers alike.

MSFHR, the BC Ministry of Health, and the governments of Quebec and Nova Scotia provided funds to Ogilvie and Dobson’s team to evaluate the relative safety of a two-dose regimen. The early buy-in from government partners meant that following the publication of their results in April 2013, provincial governments were interested in the conversation about the public health case for two doses.

By starting with a research question that was highly relevant, that was actually prioritized by a group of clinicians, policy-makers, public health specialists, and by doing that kind of research, you start to have that knowledge translation charted out.
- Gina Ogilvie

This conversation at the provincial level began to feed into a broader global dialogue about the optimal dosing schedule.

Data from the BC-led study enabled the vaccine’s manufacturer to obtain licensing from the European Medicines Agency for a two-dose regimen, which in turn caught the attention of the World Health Organization. Based on the available evidence and the commitment to a 10-year follow-up study by Ogilvie and Dobson’s team, the WHO revised its HPV policy guidelines in December 2014 to recommend a two-dose vaccine for girls aged nine to 13.

“We went from a study that was looking at the blood response to two doses versus three doses, and we ended up with a World Health Organization recommendation that two doses be the standard dosing regimen,” says Dobson. “That is an amazing story."

Research Outcomes:

HPV Vaccination

Gina Ogilvie and Simon Dobson’s initial study has had a ripple effect on HPV vaccination policies worldwide.
  • Their data was critical to the adoption of a two-dose vaccination schedule by a host of regulatory bodies, including Health Canada, the US Food and Drug Administration, and the European Medicines Agency.
  • Within six months of publication, guidelines began to reflect their finding: in October 2014, British Columbia’s HPV policy was revised to specify two doses; two months later, the recommendation was formally adopted by the World Health Organization as a new global guideline.
  • The most immediate benefit of the new policy is the cost savings from eliminating one dose per person. Each dose of the HPV vaccine costs $100, in addition to program and administrative costs. It is also hoped that fewer doses will increase compliance and boost the overall vaccination rate, which will ultimately prevent thousands of cervical cancer deaths.
Chapter 5:

The BC Advantage

Over the course of a decade or more, the researchers featured in this story have all faced challenges, both anticipated and unexpected, that tested their ability to innovate, collaborate, and improvise.


But through it all, their vision, dedication, and ability to leverage BC-based resources has resulted in product and policy breakthroughs that are changing health throughout the world.

Data resources

With centralized health records maintained by the BC Ministry of Health, BC has some of the best data resources in the world. These sources enable large-scale population-based studies of a size and quality that few other jurisdictions can match.

Collaborative infrastructure

The existence of province-wide institutions with an established track record of collaboration is vital to conducting research in BC. The coordination of resources under organizations like the Provincial Health Services Authority makes it possible for researchers to draw on diverse expertise that enhances the quality and scope of their work.

Protected time for research

The work required to turn a discovery into a commercial product is time-consuming and often at odds with the pursuit of academic novelty. For practicing clinicians, it can be particularly difficult to juggle competing demands while pursuing commercial development. The salary support provided by MSFHR Scholar Awards is essential to enabling researchers to move projects forward. By protecting time for dedicated research activity, the awards provide the freedom to focus on translating ideas into real outcomes.

An idea is a powerful catalyst for change and innovation. It is a spark of inspiration that imagines a different way of looking at the world and a call to action asking how we can do better.

But even the best ideas need to be nurtured by a supportive research ecosystem through discovery, validation, scaling up, dissemination, and adoption.

The researchers’ experiences reveal that BC can be a fertile ground for innovation. The scope of the impact BC’s research community can achieve is truly global. By working together to apply the same vision and commitment to our research enterprise that these researchers have demonstrated in their own work, we will ensure BC’s place as a recognized world leader in health innovation.

No system is perfect. There’s a world of ideas waiting to be sparked in our community of health professionals, researchers and leaders that can enhance BC’s research enterprise and unlock our province’s full potential.